Deutsch
Español
India
Italiano
Français
My Account
My Account
Notifications
Overview
+ New Watchlist
Benzinga Research
Benzinga Pro
Log In
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Get Benzinga Pro
Data & APIs
Events
Marketfy
Premarket
Boost
Advertise
Contribute
Deutsch
Español
India
Italiano
Français
Sign in
Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Government
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Options
Binary Options
Bonds
Futures
CME Group
Global Economics
Previews
Small-Cap
Real Estate
Cryptocurrency
Penny Stocks
Digital Securities
Volatility
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Covey Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Credit Cards
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Options
Binary Options
Bonds
Futures
CME Group
Global Economics
Previews
Small-Cap
Real Estate
Cryptocurrency
Penny Stocks
Digital Securities
Volatility
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Covey Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Credit Cards
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Free Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Recent
Markets
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Acasti Pharma
(NASDAQ:ACST)
Intraday
$3.04
0.10
[3.40%]
15 minutes delayed
Get Report
Watch
Perks
Buy
Compare Brokers
$3.04
0.10
[3.40%]
Last update: 4:23PM
Get Real Time Here
Get Report
Watch
Overview
News
Earnings
Guidance
Dividends
Analyst Ratings
Insider Trades
Short Interest
Latest News for Acasti Pharma Stock (NASDAQ:ACST)
Acasti Pharma Stock (NASDAQ: ACST)
Categories: All
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
Monday, February 12, 2024
Acasti Pharma Q3 EPS $(0.21) Up From $(0.52) YoY
Happy Mohamed
-
Feb 12, 2024, 8:12AM
Wednesday, February 07, 2024
Craig-Hallum Initiates Coverage On Acasti Pharma with Buy Rating, Announces Price Target of $6
Benzinga Newsdesk
-
Feb 7, 2024, 9:10AM
Thursday, February 01, 2024
Acasti Announces Poster Detailing GTX-104 STRIVE-ON Trial
Benzinga Newsdesk
-
Feb 1, 2024, 8:39AM
Thursday, January 18, 2024
Why KeyCorp Shares Are Trading Lower By Over 5%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Avi Kapoor
-
Jan 18, 2024, 1:08PM
Monday, October 23, 2023
Acasti Announces Dosing Of First Patient In GTX-104 STRIVE-ON Trial
Benzinga Newsdesk
-
Oct 23, 2023, 8:05AM
Friday, October 06, 2023
Acasti Pharma Inc Files For Shelf Of Up To 6.6M Common Shares By Selling Stockholders
Benzinga Newsdesk
-
Oct 6, 2023, 4:36PM
Thursday, September 28, 2023
Acasti Pharma 10% Owner Vimal Kavuru Reported Purchase Of 1,099,103 Shares @ Avg Price: Of $1.19/Share In Form 4 Filing On Wednesday
Charles Gross
-
Sep 28, 2023, 5:22AM
Tuesday, September 26, 2023
Why TD SYNNEX Shares Are Trading Lower By Over 5%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Lisa Levin
-
Sep 26, 2023, 12:56PM
Why Acasti Pharma (ACST) Stock Is Exploding Higher
Henry Khederian
-
Sep 26, 2023, 10:57AM
Acasti Pharma shares are trading higher after the company announced $7.5 million in private placement equity financing.
Benzinga Newsdesk
-
Sep 26, 2023, 10:27AM
Acasti Announces $7.5M Private Placement Equity Financing
Bill Haddad
-
Sep 26, 2023, 8:01AM
Wednesday, August 09, 2023
Acasti To Present GTX-104 Pharmacokinetic Comparison Data At Neurocritical Care Annual Meeting
Benzinga Newsdesk
-
Aug 9, 2023, 5:23PM
Monday, July 10, 2023
Acasti Announces WuXi Clinical As CRO To Conduct STRIVE-ON Phase 3 Safety Trial For GTX-104 In aSAH Patients
Benzinga Newsdesk
-
Jul 10, 2023, 9:08AM
Friday, July 07, 2023
Acasti Pharma Announces 1-For-6 Reverse Stock Split
Happy Mohamed
-
Jul 7, 2023, 8:03AM
Wednesday, July 05, 2023
Why 1847 Holdings Shares Are Trading Lower By Around 31%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Lisa Levin
-
Jul 5, 2023, 1:28PM
Acasti Announces Alignment With FDA On GTX-104 Pivotal Phase 3 Safety Trial Protocol And Confirms Planned Initiation Of STRIVE-ON In aSAH Patients In Calendar Q4 2023
Benzinga Newsdesk
-
Jul 5, 2023, 9:03AM
Friday, June 23, 2023
UPDATE: Acasti Pharma Q4 Adj EPS $(0.11), Inline
Benzinga Newsdesk
-
Jun 23, 2023, 8:33AM
Recap: Acasti Pharma Q4 Earnings
Benzinga Insights
-
Jun 23, 2023, 8:20AM
Acasti Pharma Q4 Adj EPS $(0.11), Inline, Cash Balance Of $27.9M
Benzinga Newsdesk
-
Jun 23, 2023, 7:47AM
Tuesday, April 04, 2023
FDA Has Allowed Acasti Pharma To Proceed With The Initiation Of GTX-104 Phase 3 Safety Clinical Trial In Aneurysmal Subarachnoid Hemorrhage Patients
Benzinga Newsdesk
-
Apr 4, 2023, 8:09AM
Wednesday, February 15, 2023
EF Hutton Reiterates Buy on Acasti Pharma, Maintains $2.5 Price Target
Benzinga Newsdesk
-
Feb 15, 2023, 7:02AM
Tuesday, February 14, 2023
Acasti Pharma Q3 EPS $(0.09) Beats $(0.11) Estimate, Cash Balance Of $31.3M With Cash Runway Into Q2 Of 2024
Benzinga Newsdesk
-
Feb 14, 2023, 7:04AM
Earnings Scheduled For February 14, 2023
Benzinga Insights
-
Feb 14, 2023, 4:44AM
Monday, February 13, 2023
Acasti Pharma's Earnings Outlook
Benzinga Insights
-
Feb 13, 2023, 9:01AM
Wednesday, January 25, 2023
Acasti Receives Extension To Regain Compliance With NASDAQ Minimum Bid Price Rule
Benzinga Newsdesk
-
Jan 25, 2023, 9:02AM
Tuesday, January 17, 2023
Acasti Pharma Discusses Clinical Study Results For GTX-101 And GTX-102 And Upcoming Phase 3 Study For GTX-104 With The Stock Day Podcast
Benzinga Newsdesk
-
Jan 17, 2023, 8:49AM
Friday, January 06, 2023
Why Graphite Bio Shares Are Trading Lower By 50%; Here Are 20 Stocks Moving Premarket
Lisa Levin
-
Jan 6, 2023, 8:00AM
Thursday, January 05, 2023
Acasti To Host Conference Call On Tuesday, January 10, 2023 To Discuss Results From Recent Phase 1 PK Studies For GTX-101 And GTX-102 That Met All Outcome Measures
Benzinga Newsdesk
-
Jan 5, 2023, 9:13AM
Wednesday, December 28, 2022
Acasti Pharma shares are trading higher after the company announced preliminary topline results met all outcome measures in the pharmacokinetic bridging study for GTX-102, the company's drug candidate for the treatment of Ataxia Telangiectasia.
Benzinga Newsdesk
-
Dec 28, 2022, 8:19AM
Acasti Announces Preliminary Topline Results Met All Outcome Measures In Pharmacokinetic Bridging Study For GTX-102, The Company's Drug Candidate For Treatment Of Ataxia Telangiectasia
Bill Haddad
-
Dec 28, 2022, 8:05AM
Friday, December 23, 2022
Why Applied Molecular Transport Shares Are Trading Lower By Over 55%? Here Are 47 Stocks Moving In Friday's Mid-Day Session
Lisa Levin
-
Dec 23, 2022, 1:24PM
Why DBV Technologies Shares Are Trading Higher By 38%; Here Are 26 Stocks Moving Premarket
Lisa Levin
-
Dec 23, 2022, 7:47AM
Thursday, December 22, 2022
Acasti Pharma Announces Preliminary Topline Results Met All Primary Outcome Measures In Single Dose Pharmacokinetic Study For GTX-101
Bill Haddad
-
Dec 22, 2022, 8:11AM
Tuesday, December 20, 2022
Why IceCure Medical Shares Are Trading Higher By 296%? Here Are 64 Stocks Moving In Tuesday's Mid-Day Session
Lisa Levin
-
Dec 20, 2022, 1:19PM
Monday, December 19, 2022
Benzinga's Top Ratings Upgrades, Downgrades For December 19, 2022
Benzinga Insights
-
Dec 19, 2022, 10:00AM
EF Hutton Initiates Coverage On Acasti Pharma with Buy Rating, Announces Price Target of $2.5
Benzinga Newsdesk
-
Dec 19, 2022, 7:11AM
Thursday, December 15, 2022
Benzinga's Top Ratings Upgrades, Downgrades For December 15, 2022
Benzinga Insights
-
Dec 15, 2022, 10:02AM
HC Wainwright & Co. Initiates Coverage On Acasti Pharma with Buy Rating, Announces Price Target of $2.4
Benzinga Newsdesk
-
Dec 15, 2022, 7:42AM
Friday, December 09, 2022
Stocks That Hit 52-Week Lows On Friday
Benzinga Insights
-
Dec 9, 2022, 12:45PM
Wednesday, December 07, 2022
Stocks That Hit 52-Week Lows On Wednesday
Benzinga Insights
-
Dec 7, 2022, 11:38AM
Monday, November 14, 2022
Stocks That Hit 52-Week Lows On Monday
Benzinga Insights
-
Nov 14, 2022, 12:42PM
Acasti Pharma Q2 EPS $(0.11) Down From $0.03 YoY
Benzinga Newsdesk
-
Nov 14, 2022, 7:17AM
Earnings Scheduled For November 14, 2022
Benzinga Insights
-
Nov 14, 2022, 5:06AM
Friday, November 11, 2022
Stocks That Hit 52-Week Lows On Friday
Benzinga Insights
-
Nov 11, 2022, 12:07PM
Thursday, November 10, 2022
Stocks That Hit 52-Week Lows On Thursday
Benzinga Insights
-
Nov 10, 2022, 11:29AM
Monday, October 17, 2022
Stocks That Hit 52-Week Lows On Monday
Benzinga Insights
-
Oct 17, 2022, 11:32AM
Friday, October 14, 2022
121 Stocks That Hit Their 52-Week Low
Benzinga Insights
-
Oct 14, 2022, 11:49AM
Friday, September 30, 2022
Acasti Announces Court Dismissal of Stockholder Litigation
Benzinga Newsdesk
-
Sep 30, 2022, 9:09AM
Friday, September 16, 2022
Stocks That Hit 52-Week Lows On Friday
Benzinga Insights
-
Sep 16, 2022, 2:08PM
Wednesday, September 07, 2022
Stocks That Hit 52-Week Lows On Wednesday
Benzinga Insights
-
Sep 7, 2022, 1:08PM
Show more